VENUSREM · Venus Remedies Ltd. · NSE · Filed 20 Jul · 2 min read

Venus Remedies posts higher June-quarter profit; auditors flag pending German subsidiary matter

The drugmaker reported year-on-year growth in June-quarter revenue and profit, while its board revised a proposed change to the company's Memorandum of Association and auditors flagged an emphasis-of-matter note on its wholly owned German unit.

What the board approved

At its meeting on 20 July 2026, the Venus Remedies board took two principal actions. It approved the unaudited standalone and consolidated results for the quarter ended 30 June 2026, together with the statutory auditor's limited review report. Separately, it approved certain revisions to a previously proposed alteration of the company's Memorandum of Association (MOA) and Articles of Association.

Per the filing, the MOA revisions are intended to align the Object Clause with the Companies Act, 2013 and to update the main and ancillary objects to reflect the company's current and proposed business activities. The company stated that its principal business remains unchanged and that it continues to operate in the pharmaceutical sector. The revised MOA will go before members for approval by special resolution at the forthcoming 37th Annual General Meeting.

The quarter's numbers

The June-quarter results show revenue and profit both higher than the corresponding quarter a year earlier, on both standalone and consolidated bases, though below the seasonally larger March quarter. The auditors issued an unmodified limited review conclusion on both statements. The specific figures appear in the key-facts panel below.

The German subsidiary note

The auditors drew attention to an emphasis-of-matter item concerning Venus Pharma GmbH, the company's wholly owned German subsidiary. Share application money remains outstanding because formal share allotment is not mandatory under German law. Management described the investment as strategic and said it intends to recover the amount in due course as part of a restructuring of European operations in FY 2026-27. The filing states that the subsidiary is currently facing financial challenges, and that the company has reiterated its intention to provide financial and operational support during the transition. The auditors' conclusion was not modified in respect of this matter. The company said it has engaged a Germany-based financial consultancy firm to advise on the appropriate framework and mechanism.

Revenue from operations (standalone, prior-year Q1): ₹137.13 → ₹178.80 crQ1 FY26 → Q1 FY27+30%^‡
Net profit (standalone, prior-year Q1): ₹11.70 → ₹25.53 crQ1 FY26 → Q1 FY27+118%^‡
Revenue from operations (consolidated, prior-year Q1): ₹137.18 → ₹178.86 crQ1 FY26 → Q1 FY27+30%^‡
Net profit (consolidated, prior-year Q1): ₹9.60 → ₹22.97 crQ1 FY26 → Q1 FY27+139%^‡

Profit before tax (standalone, Q1): ₹32.60 crore
EBIDTA (standalone, Q1): ₹39.11 crore
Basic EPS (standalone, Q1): ₹19.40
Outstanding share application money — Venus Pharma GmbH: INR 2,859.72 Lakhs

‡ Computed by us from the filing’s own figures — not a company-stated number.

For holders, the filing packages the June-quarter earnings with two items that touch governance and exposure: a proposed rewrite of the company's stated objects going to a shareholder vote at the 37th AGM, and an auditor emphasis-of-matter note describing a financially challenged German subsidiary and the pending share application money tied to it. Both are disclosures to note rather than any indication of future outcome.